This paper, published in “Aesthetic Dermatology” focuses on non-scarring alopecia in women, a distressing and common problem. Hair loss can have a devastating psychological impact, and understanding the different types and treatment options is crucial for managing the condition. To gain a complete understanding of the topic, we encourage you to download the full paper.
What is Non-Scarring Alopecia?
Non-scarring alopecia is the most common type of hair loss in women. Diffuse hair loss is the most frequent presentation, and is primarily of two types: telogen effluvium and female pattern hair loss (FPHL).
- Telogen Effluvium: This occurs when hair follicles synchronize and enter a resting phase together, which can happen after emotional stress or postpartum. In acute cases, shedding lasts less than six months and then recovers. Chronic telogen effluvium, however, involves hair shedding over a longer period and may have a physiological cause such as hypothyroidism, iron deficiency, or low serum vitamin D. Certain medications, including beta blockers, ACE inhibitors, and warfarin, can also cause hair loss.
- Female Pattern Hair Loss (FPHL): This is characterized by gradual thinning of the hair over the central scalp. It is the most common cause of hair loss in women, affecting up to 40% of women aged 70 years. Unlike male pattern baldness, the role of androgens is less clear, with studies showing normal androgen levels in 70% of FPHL cases.
Treatment Options
If no underlying cause for the hair loss is found, treatment requires careful planning. For FPHL, a non-androgen related treatment should be tried first.
- Topical Minoxidil: This is the most commonly used non-androgen treatment for FPHL. It does not alter the natural history of hair loss but can thicken or increase the density of the remaining hair. Treatment needs to be lifelong, with results assessed at six and 12 months.
- Anti-androgens: In women with androgen-related loss or those who do not respond to minoxidil, a combination of anti-androgen and non-androgen treatment should be considered. However, no anti-androgen is currently approved for FPHL, and they should not be used in pregnancy due to the risk of feminisation of a male fetus.
- Hair Transplantation: This is an option for women in whom medical treatment has failed. However, it is an expensive procedure, and donor sites can be limited in women.
- Wigs and Hair Extensions: These can also be very useful and help to improve a patient’s quality of life and self-esteem.
- Other Treatments: Less evidence-based treatments include low-level light therapies (LED and laser) and platelet-rich plasma.
Download the full paper on non-scarring alopecia in women to learn more.